Kabuki syndrome 1 (KS1) is a Mendelian disorder of the epigenetic machinery caused by mutations in the gene encoding KMT2D, which methylates lysine 4 on histone H3 (H3K4). KS1 is characterized by intellectual disability, postnatal growth retardation, and distinct craniofacial dysmorphisms. A mouse model (Kmt2d +/bGeo ) exhibits features of the human disorder and has provided insight into other phenotypes; however, the mechanistic basis of skeletal abnormalities and growth retardation remains elusive. Using high-resolution micro-computed tomography we show that Kmt2d +/bGeo mice have shortened long bones and ventral bowing of skulls. In vivo expansion of growth plates within both the skull and long bones suggests disrupted endochondral ossification as a common disease mechanism. Stable chondrocyte cell lines harboring inactivating mutations in Kmt2d exhibit increased proliferation and differentiation, which further supports this mechanism. A known inducer of chondrogenesis, SOX9, and its targets show markedly increased expression in Kmt2d -/chondrocytes. By transcriptome profiling, we identify Shox2 as a putative KMT2D target. We propose that decreased KMT2D-mediated H3K4me3 at Shox2 releases Sox9 inhibition and thereby leads to enhanced chondrogenesis, providing a novel and plausible explanation for precocious chondrocyte differentiation. Our findings not only provide insight into the pathogenesis of growth retardation in KS1, but also suggest novel therapeutic targets to rescue growth retardation in KS1 and related disorders.
Introduction
Mendelian disorders of the epigenetic machinery disrupt the fundamental processes of neurological development and growth (1) . This rapidly growing group of inherited conditions resulting from germ-line mutations in components of the epigenetic machinery is expected to have broad epigenomic consequences.
Despite growth abnormalities being the second most common disease manifestation, molecular underpinnings have not been examined in detail but could provide insight into disease mechanisms that may be broadly applicable to other more common growth disorders, like idiopathic short stature.
Kabuki syndrome (KS; MIM 147920), an autosomal dominant Mendelian disorder of the epigenetic machinery (1) , results from heterozygous typically de novo inactivating mutations in KMT2D (2) , which encodes an epigenetic writer that normally catalyzes histone methylation on H3 at lysine 4 (H3K4me).
Individuals with Kabuki syndrome 1 (KS1) exhibit the cardinal phenotypic features of postnatal growth retardation, intellectual disability, and craniofacial abnormalities (3, 4) . The distinct craniofacial features that are characteristic of KS1 include flattening of the facial profile, elongated palpebral fissures with eversion of the lower eyelids, highly arched and interrupted eyebrows, short columella with a depressed nasal tip, prominent ears, and palate abnormalities; these often provide the best clue for clinical diagnosis in affected individuals (5) (6) (7) . Shott et al. systematically evaluated growth patterns in individuals with molecularly-confirmed KS1, revealing postnatal growth retardation in the vast majority (8) and confirming previous reports from clinically diagnosed patients (9) (10) (11) . Most of the molecularly-confirmed individuals with KS1 did not meet criteria for growth hormone deficiency (12) . Despite this, treatment with recombinant growth hormone therapy improved linear growth in some but not all individuals with KS1 (13) . Such observations demonstrate the lack of knowledge about the underlying mechanism of growth retardation in KS1 and suggest it is more complex than isolated growth hormone deficiency.
Using morpholinos to knock down Kmt2d in zebrafish, Van Laarhoven et al. postulated a defect in neural crest-derived cell function in the development of facial flattening in fish deficient in Kmt2d because multiple cartilaginous structures were underdeveloped (14) . In our previous work we characterized a mouse model of KS1, which exhibits many features seen in patients with the disorder (15) . Kmt2d +/bGeo mice have disrupted H3K4 trimethylation (H3K4me3) in the dentate gyrus of the hippocampus and associated neurogenesis defects and memory deficits. All three features could be reversed by postnatal administration of agents that favor chromatin opening such as HDAC inhibitors or the HDAC inhibitor-like ketone body, betahydroxybutyrate (15, 16) . Kmt2d +/bGeo mice also weigh less than Kmt2d +/+ littermates and exhibit a flattened facial profile like individuals with KS1 (15) . The cellular and molecular basis for this phenotype has not been examined.
Here, using high-resolution micro-computed tomography (micro-CT), we elucidate a robust and quantitative skeletal growth retardation phenotype impacting the long bones and cranial base of the skull in Kmt2d +/bGeo mice. Histological data from growth plates within both sites suggest a unifying mechanism of disrupted endochondral ossification. Our in vitro studies of stable chondrocyte cell lines harboring loss of function Kmt2d mutations provide further evidence that increased proliferation and precocious differentiation of chondrocytes play a key role in KS1 pathogenesis. Targeted and genome-wide transcriptome profiling supports precocious differentiation of chondrocytes, and together with targeted chromatin immunoprecipitation studies, suggests the basis for Sox9 dysregulation. This involves loss of KMT2D-mediated H3K4me3 at an unsuspected target, Shox2, causing release of Sox9 inhibition, and thereby precocious chondrocyte differentiation. Our findings provide novel mechanistic insight into the pathogenesis of growth retardation in KS1 and related disorders and suggest potential novel therapeutic targets.
Results

Kmt2d +/bGeo mice exhibit a specific skeletal growth retardation phenotype
Kmt2d +/bGeo mice are smaller than Kmt2d +/+ littermates, both grossly (15) and on lateral radiographs ( Figure 1A) . Quantification of body weight ( Figure 1B) and length ( Figure 1C) with repeated observations using mice at multiple ages (Supplemental Figure 1A) confirmed growth retardation in Kmt2d +/bGeo mice.
Because detailed quantification on radiographs revealed a decrease in upper jaw length in Kmt2d +/bGeo mice compared to Kmt2d +/+ littermates (data not shown), we first performed high-resolution micro-CT analysis of the skulls of Kmt2d +/bGeo mice and Kmt2d +/+ littermates to examine the craniofacial phenotype. Reconstructed micro-CT images unequivocally confirm a striking flattening of the facial profile in Kmt2d +/bGeo mice compared to Kmt2d +/+ littermates (Figure 1D) , which resembles the facial flattening seen in individuals with KS (17) .
To further characterize the craniofacial phenotype, we performed morphometric analyses of three- mice exhibit a distinct defect in skeletal growth that is evident at multiple sites and resembles that observed clinically in KS1.
In vivo and in vitro studies suggest disrupted endochondral ossification in KS1
Long bones, as well as a few bones in the skull, increase in length by means of endochondral ossification at growth plates, which involves proliferation and hypertrophy of chondrocytes and production of cartilaginous matrix that is ultimately replaced by bone laid down by osteoblasts. The pattern of growth abnormalities in Kmt2d +/bGeo mice suggests alterations in growth plate dynamics as a potential mechanism for the defects observed in long bones and the cranial base. Therefore we stained longitudinal sections from 3 ). Therefore we examined the cranial base, a key area of the skull that grows by endochondral ossification, and another site which also appears to be shortened in individuals and mice with KS1 (Figure 1) .
Examination of intrasphenoidal synchondroses, which are partly responsible for growth of the cranial base in the anterior-posterior direction (18) , revealed a similar expansion in Kmt2d +/bGeo mice compared to Kmt2d +/+ littermates (Figure 3G-H) . While counterintuitive that growth plate height could be expanded whilst the cranial base and long bones themselves were shortened in length, these findings suggest that abnormal endochondral ossification of long bones and of the cranial base are a unifying mechanism for the skeletal phenotype of KS1 mice.
To understand the cellular basis for this phenotype, we employed a more manipulatable system of chondrocyte development, the well-established ATDC5 cell system; upon induction, these mesenchymal progenitors progress through the stages of chondrocyte development, including proliferation and hypertrophy (19) . Using CRISPR-Cas9 genome editing technology, we created stable cell lines with homozygous mutations of varying severity, Kmt2d DR5551/-, which has a deletion of a single amino acid on one allele and deletion of the Figure 5B ) indicated that loss of Kmt2d function increases chondrocyte replication in accordance with the severity of the mutation. This was evident at 4-7 days postdifferentiation induction. These findings support our previous observation of proliferative zone expansion in proximal tibia growth plates from Kmt2d +/bGeo mice (Figure 3A, C, E) . Similarly, cultures of Kmt2d -/cells exhibited more dramatic increases in matrix deposition, as indicated by alcian blue staining, when compared to Kmt2d +/+ controls with Kmt2d DR5551/cells having an intermediate phenotype (Figure 4A-B) . By fourteen days after induction of differentiation, we observed a significant increase in alcian blue staining of Kmt2d -/chondrocytes compared to Kmt2d DR5551/and Kmt2d +/+ chondrocytes (Figure 4A-B ). This increase was progressive and exceedingly apparent at day 21. These data suggest precocious differentiation of Kmt2d -/cells and fits with the expansion of hypertrophic zones observed in proximal tibia growth plates from 
Overexpression of Sox9 mediates the precocious differentiation phenotype
We hypothesized that Sox9, which encodes a key transcription factor that promotes chondrocyte differentiation and is a known direct activator of Col2a1 and Col10a1 (20) , could be a potential candidate gene to mediate our cellular phenotype. SOX9 facilitates chondrocyte differentiation through proliferation and hypertrophy and prevents further progression toward bone-forming osteoblasts (20) . The level of expression of to proceed precociously and at the expense of osteoblast differentiation ( Figure 4F ).
Loss of Shox2 expression and release of Sox9 inhibition in a KS1 chondrocyte model
We performed genome-wide transcriptome profiling by RNA-seq using RNA from Kmt2d -/and Kmt2d +/+ chondrocytes 7 days after induction of differentiation to identify KMT2D targets that can inhibit Sox9 ( Figure   5A ; Supplemental Figure 6A ; Supplemental Table S1 ). Day 7 appears to be a key time point for gene expression changes that lead to precocious differentiation because immediately after day 7 alcian blue staining increases significantly in Kmt2d -/chondrocytes compared to Kmt2d +/+ chondrocytes (Figure 4A,B) , and just prior to day 7 we observed a striking difference in expression of Sox9 between Kmt2d -/and Kmt2d +/+ chondrocytes ( Figure 4E) . For comparison, we also performed RNA-seq on undifferentiated Kmt2d -/and Supplemental Table S2 ).
Multiple observations emerged from our transcriptome profiling. First, principal components analysis revealed highly correlative data with tight clustering within and distinct separation between genotypes and differentiation states, separating the cells into 4 distinct groups (Kmt2d +/+ undifferentiated cells, Kmt2d +/+ chondrocytes, Kmt2d -/undifferentiated cells, and Kmt2d -/chondrocytes) with differentiation state (chondrocytes versus undifferentiated cells) explaining a greater percentage of the variance than genotype (Kmt2d -/versus Kmt2d +/+ ; Figure 5C ). Second, differential expression analysis revealed multiple expected gene expression changes, including greater than 50-fold upregulation of Col2a1 in Kmt2d -/cells compared to Supplemental Table S2;   Tables 1-2) , similar to our previous observations ( Figure 4C ). In addition, we observed consistent 3-4 fold upregulation of the master transcriptional regulator of chondrogenesis, Sox9, in Kmt2d -/cells compared to Kmt2d +/+ cells in both differentiation states (Figure 5A-B ; Supplemental Tables S1-3 Supplemental Table S1 ), and Col10a1 (4-fold in undifferentiated cells; Supplemental Table   S2 ; compare to Figure 4D ), further supporting a mechanism involving precocious chondrocyte differentiation. Lastly, we observed more differential gene expression within a single genotype, Kmt2d +/+ (7,201 genes; Supplemental Table S5 ) or Kmt2d -/-(4,764 genes; Supplemental Table S6 ), over the course of differentiation from mesenchymal cells to chondrocytes compared to the differential expression observed between genotypes within a particular differentiated state, i.e. chondrocytes Kmt2d -/versus Kmt2d +/+ (932 genes; Supplemental   Table S1 ) or undifferentiated mesenchymal cells Kmt2d -/versus Kmt2d +/+ (1009 genes; Supplemental Table   S2 ). This is expected and suggests that the number of gene expression changes required for a cell to undergo a differentiation program is greater than the number that result from loss of function of a single gene, even if that gene is a component of the epigenetic machinery with many downstream direct targets and indirect consequences.
Comparing Kmt2d -/chondrocytes to Kmt2d +/+ chondrocytes, we found 932 differentially expressed genes with 486 upregulated and 446 downregulated (Figure 5A; Supplemental Figure 6A ; Supplemental   Table S1 ). There were 1009 differentially expressed genes when Kmt2d -/and Kmt2d +/+ undifferentiated cells were compared with 474 being upregulated and 535 being downregulated (Figure 5B; Supplemental Figure   6B ; Supplemental Table S2 ). Of those differentially expressed genes, 382 are common across differentiation state (i.e. found in both chondrocytes and undifferentiated cells; Supplemental Table S3) Table S4 ). We hypothesized that direct KMT2D targets would have more dramatic gene expression abnormalities and thus focused on the subset that were downregulated at least 4-fold in Kmt2d -/cells (Supplemental Table S4 ). We searched the literature to identify whether any of the 44 genes had previously been reported as targets of KMT2D, regulators (particularly inhibitors) of Sox9, and/or involved in chondrocyte development. No known KMT2D targets were among the 44 genes identified by our transcriptome analysis to be down-regulated at least 4-fold in Kmt2d -/cells. Three genes were identified as being involved in chondrocyte development and connected with Sox9 in the literature; however, only one had the potential to negatively regulate Sox9 based on previous studiesthe transcription factor Shox2.
Shox2 is the most intriguing candidate gene down-regulated over 4-fold (Supplemental Table S4 Figure 6B ). Shox2 is the mouse paralogue to the human SHOX gene, which when disrupted causes short stature (23) (24) (25) . Shox2 is important in mice for long bone growth and chondrocyte development (26, 27) , and importantly, conditional deletion in chondrocytes leads to precocious differentiation with concomitant increase in Col2a1 and Sox9 expression (26), similar to what we observed in Kmt2d -/cells (Figure 4C,E) . We confirmed that Shox2 is downregulated over 4-fold in Kmt2d -/cells compared to Kmt2d +/+ cells in the undifferentiated state and in chondrocytes by qPCR in three independent experiments ( Figure 5D ).
Functional testing supports the idea that Shox2 plays a mechanistic role in the cellular differentiation phenotype
Based on these observations, we hypothesized Shox2 may be a target of KMT2D and a mediator of the precocious differentiation observed in Kmt2d -/cells. KMT2D places the H3K4me3 activating mark at gene promoters (28) , and we previously showed depletion of this mark in the hippocampi of Kmt2d +/bGeo mice (15) .
Moreover, examination of ENCODE data from mouse limb bud revealed a strong peak of H3K4me3 at the 5' end of the Shox2 gene (29, 30) ; Supplemental Figure 7A ). We therefore performed chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) using an antibody that specifically recognizes were not significantly different than those observed in Kmt2d +/+ cells (Figure 5F) . These results indicate that overexpression of Shox2 is sufficient to inhibit and therefore restore Sox9 expression to near wild type levels and supports a key role for SOX9 in precocious chondrocyte differentiation in KS1.
To determine if overexpression of Shox2 can fully restore the cellular differentiation phenotype in previously observed in KS2 (32) , but also likely present in KS1. Additional studies will be required to fully understand the pathogenesis of the craniofacial phenotype in KS1 and KS2.
Here we implicate SOX9 in the pathogenesis of the KS1 skeletal phenotype. Our initially unexpected observations of growth plate expansion in the setting of decreased growth at distinct sites in KS1 mice suggested disrupted endochondral ossification as a mechanism and the chondrocyte as a relevant cell type. A more dynamic system of chondrocyte development, stable ATDC5 cell lines with Kmt2d loss of function mutations, confirmed precocious chondrocyte differentiation at the cellular and gene expression levels, thereby suggesting a cell-autonomous phenotype reconstituted in an isogenic model. Our findings point to a novel mechanism of loss of KMT2D-mediated release of inhibition of Sox9, leading to unchecked and precocious chondrocyte differentiation. Supporting our findings, Sox9 is a well-known mediator of chondrocyte differentiation required for cartilage formation (33) (34) (35) . Monoallelic loss of function mutations in humans lead to campomelic dysplasia, a severe chondrodysplasia (36, 37) , and heterozygous ablation in mice resembles the human phenotype (34) . Conditional ablation in differentiated chondrocytes disrupts endochondral ossification resulting in severely shortened growth plate heights and reveals that Sox9 expression is necessary for chondrocyte proliferation and late stages of hypertrophy (20) . This is consistent with our findings of both increased chondrocyte proliferation and precocious differentiation (hypertrophy) in Kmt2d -/stable cell lines in the setting of increased expression of Sox9. SOX9 is known to directly activate multiple chondrocyte-specific factors, including early and late markers of chondrogenesis, like Col2a1 and Col10a1, respectively (20, 33) , which are also dysregulated and may be a measure of SOX9's down-stream effects although it is unlikely that these are the only genes dysregulated secondary to increased Sox9 expression. Moreover, loss of KMT2D leading to release of Sox9 inhibition and subsequent activation of early and late effectors of chondrogenic differentiation would explain our observed increases in proliferative zone, hypertrophic zone, and overall growth plate heights in Kmt2d +/bGeo mice.
In addition to facilitating chondrocyte differentiation, SOX9 also prevents osteoblast differentiation (20) .
The net effect of this imbalance between precocious chondrocyte differentiation and reduced osteoblast differentiation may lead to growth retardation in KS1, specifically to shortening of the long bones and decreased bone formation in Kmt2d +/bGeo mice. In support of this, when we measured osteoblast differentiation by alizarin red staining, we saw that newly formed bone was decreased in Kmt2d +/bGeo mouse bone marrow mesenchymal stem cells compared to cells derived from Kmt2d +/+ mice (data not shown). However, future conditional studies will be required to reveal the exact impact in individual lineages.
We used genome-wide transcriptome profiling by RNA-seq to identify KMT2D target genes and associated molecular pathways that may play a role in KS1 pathogenesis. We identified Shox2 as a novel target of KMT2D. Shox2 was downregulated over 4-fold in Kmt2d -/chondrocytes and undifferentiated mesenchymal cells. Depletion of the H3K4me3 activating mark placed by KMT2D at the Shox2 promoter in Kmt2d -/cells supports this new finding as a direct interaction between KMT2D and the Shox2 promoter. We propose that loss of KMT2D (and thus H3K4me3) in chondrocytes and their precursors leads to decreased Shox2 expression and subsequent release of Sox9 inhibition; this leads to increased SOX9, which activates the chondrocyte differentiation program prematurely, including overexpression of Col2a1 and Col10a1, and leads to precocious differentiation of chondrocytes.
Our finding of Shox2 as a potential direct target of KMT2D is intriguing and quite relevant to the KS1 phenotype. A transcription factor highly conserved between mouse and humans (38, 39) , Shox2 is expressed in developing limbs, the palate, the central nervous system, and the heart in both species (38) , as well as in additional pharyngeal arch-derived craniofacial structures and the nasal process in humans. Notably, all of these tissues are affected in KS1 with its associated findings of developmental delay/intellectual disability, short stature/lower limb shortening, congenital heart disease, and well-documented craniofacial phenotype, including flattening of the facial profile due to short columella and depressed nasal tip, as well as ear and palate abnormalities and hearing loss (5, 40) . No congenital disorders in humans have yet been attributed to SHOX2 intragenic mutations to determine whether this might lead to a phenocopy of KS. Contiguous gene deletions and duplications involving human chromosome 3q25-3q26 including Shox2 and/or its known regulatory elements have been described, however, and these individuals have intellectual disability, skeletal and growth abnormalities, and dysmorphic facial features (41) (42) (43) , resembling aspects of the KS phenotype.
Neural-specific conditional ablation of Shox2 leads to poor cerebellar development associated with precocious differentiation of neural progenitors and motor coordination deficits (44) , supporting a functional role for SHOX2 in neurological development and potentially implicating it in motor delays, a key aspect of the KS1 phenotype. It is worth mentioning that mShox2, our novel KMT2D target, is the most closely related gene to the better-known hSHOX gene, which is known to cause multiple short stature syndromes with associated mesomelia (23) (24) (25) and to contribute to the short stature seen in Turner syndrome (23, 46) . Moreover, a subset of individuals with Turner syndrome have a KS phenotype (47) (48) (49) (50) . SHOX and SHOX2 are thought to exhibit functional redundancy in humans with no known mouse SHOX homologue (38, 39) , suggesting that SHOX2 may perform the overlapping functions of both genes in mice (39) . In humans, SHOX is thought to mainly pattern the distal limb segment (tibia/radius) while SHOX2 may be more important in patterning the proximal limb segment (femur/humerus; 39). Because both proximal femurs and distal tibias are shortened in Kmt2d +/bGeo mice, our studies fit with prior work and suggest SHOX2 may indeed serve dual functions. Based on our molecular studies in mice and data from humans with KS1, we hypothesize that SHOX2 may be a target of KMT2D in humans as well, and we argue that SHOX2 is a more likely target than SHOX based on two observations. First, a hallmark of every SHOX-associated disorder is mesomelic upper limb shortening, and humans with KS1 were shown to have disproportionately long arms (31) , disfavoring SHOX as a key target of KMT2D and mediator of skeletal growth retardation in human KS1. Second, the expression patterns of mShox2 and hSHOX2 are more similar than mShox2 and SHOX, and the tissue distribution of expression of hSHOX2 overlaps almost exactly with the key tissues affected in KS1, including skeletal and others. Because SHOX is expressed in a subset of those tissues, we cannot rule out its involvement; however, our findings favor SHOX2 as a mediator of key aspects of KS1.
Our findings reveal the first mechanistic insights into the molecular basis of the skeletal growth retardation phenotype and the highly characteristic facial appearance of KS1. We have characterized and quantified a robust skeletal growth retardation phenotype in KS1 mice, which resembles the human condition and involves disrupted endochondral ossification at distinct sites. Furthermore, we have elucidated a novel mechanism involving loss of KMT2D-mediated H3K4me3 at a new target (Shox2) and release of SOX9 inhibition, which allows precocious chondrocyte differentiation to proceed unchecked. Partial rescue of the KS1 chondrocyte gene expression profile through modulation of a single disrupted target gene, Shox2, fits with our model that KMT2D acts on multiple targets, some of which have key functional consequences. This is encouraging for future development of therapeutics directed against key epigenetic machinery targets implicated in KS1 and related disorders but suggests a broader therapeutic approach may be required in some cases. The previously identified roles of SHOX2 in skeletal tissues including long bones and the palate, as well as in other tissues relevant to KS, like cerebellum, point to additional potential roles for this gene in the pathogenesis of KS1 and related disorders and suggest additional therapeutic benefits to targeting SHOX2 for the treatment of diverse manifestations of KS, other Mendelian disorders of the epigenetic machinery, and more common disease states that disrupt normal growth and development.
Materials and Methods
Mice
Kmt2d +/bGeo mice have been previously described (15, 16) . Mice were housed in a clean, specific pathogen-free state-of-the-art animal facility in ventilated racks and provided ad lib access to a standard rodent diet and to filtered water via an automatic watering system. All mice used in these studies were approximately 6 weeks of age unless otherwise noted, and littermates were used as controls in all experiments. Analyses were performed in a blinded manner unless otherwise noted. A single Kmt2d +/+ mouse was excluded from all analyses due to being obviously runted and for having gross midfacial asymmetery related to incisor malocclusion, making this animal an outlier with respect to size, craniofacial shape/asymmetry, and micro-CT parameters. Otherwise, no outliers were excluded from any comparisons or statistical calculation.
High-resolution micro-computed tomography
Femurs, tibias, and skulls were fixed in 4% paraformaldehyde, washed, and transferred to 70% ethanol. Highresolution images were acquired using a desktop micro-tomographic imaging system (Skyscan 1172, Bruker)
in accordance with the recommendations of the American Society for Bone and Mineral Research (ASBMR; (51) . Full length scans were reconstructed with NRecon software (Bruker). Femurs and tibias were scanned at 65 keV and 153µA using a 1.0 mm aluminum filter with an isotropic voxel size of 10 µm. In the femur, trabecular bone parameters were assessed in a region of interest 500 µm proximal to the growth plate and extending for 2 mm (200 CT slices) using CtAn software (Bruker). Cortical bone structure was assessed in the femur using a 500µm region of interest centered on the mid-diaphysis. Skulls were scanned at an isotropic voxel size of 10-28 µm at 80 keV and 120µA.
Craniofacial morphometric analysis
We used geometric morphometrics to test the effect of the Kmt2d +/bGeo mutation on craniofacial structure.
MicroCT image volumes of the head were obtained for a comparative adult sample of Kmt2d +/bGeo mice (N=13) and Kmt2d +/+ littermates (N=21), as described above (scan parameters: 80 keV and 120µA.; reconstruction:
0.010-0.028mm cubic voxels). Images were reconstructed using Amira post-processing software (v. 6.1.1, FEI), and 3D models of the skull were extracted based on density thresholds. The shape of the cranium was estimated by collecting three-dimensional coordinate data in Amira for biologically relevant, homologous landmarks (K=18; see Fig. 1E ). We used MorphoJ software to produce a Procrustes superimposition of all landmark configurations (52) and, based on the assumption of object symmetry for the skull, analyzed only the symmetric portion of variance to minimize the effects of subtle asymmetries (53) . Principal components analysis (PCA) was applied to visualize the most influential patterns of shape variance within the combined sample, and Procrustes ANOVA was used to test the effect of the mutation on overall cranial shape.
Histology and histomorphometry
Tibias and skulls were fixed in 4% paraformaldehyde and then transferred to 10-14% EDTA for decalcification.
Decalcified tibias and skulls were then processed, embedded, sectioned, and stained with hematoxylin and eosin (H and E). Images were taken using a Nikon 80i microscope and analyzed using NIS elements software. Antibody specific for KMT2D (Millipore; ABE1867) was used to verify protein levels by Western blot analysis.
Chondrocyte differentiation ATDC5 stable cell lines (Kmt2d +/+ , Kmt2d DR5551/-, Kmt2d -/-) were seeded in the above medium at 1× 10 5 cells/well in 6-well plates (alcian blue staining; RNA isolation), at 1×10 3 cells/well in 96-well plates (MTT assay), and at 6.3 × 10 3 cells/well in a 24-well plates (cell counting). The next day and every 2-3 days thereafter, medium was replaced with chondrogenic differentiation medium: DMEM/ Ham's F12 supplemented with 5% FBS, 100 units/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 1X Insulin-Transferrin-Selenium (Gibco), 50 μg/ml L-ascorbic acid and 10 mM β-glycerophosphate (MilliporeSigma). Cells were harvested at 0, 4, 7, 14, and 21 days.
Alcian blue staining
At the indicated time points, cells were fixed in 4% paraformaldehyde, stained with alcian blue (Sigma-Aldrich), and microscopically evaluated. After permeabilization with 1% SDS, absorbance was measured at 605 nm using a Biotek synergy 2 plate reader.
MTT cell proliferation assay
At the indicated time points, 10 μL of cell proliferation reagent (MTS) was added to the medium and incubated at 37° C, 5% CO2 for 1.5 hrs, as per manufacturer's recommendation (Promega). Absorbance was measured at 490 nm using a Biotek synergy 2 plate reader.
Cell counting assay
At the indicated time points, cells were trypsinized and stained with a 0.4 % trypan blue solution (Corning).
Cells were manually counted using a hemocytometer.
Quantitative RT-PCR
Total RNA was isolated using TRIZOL reagent according to the manufacturer's instructions (Invitrogen) at the indicated time points. Reverse transcription was performed using the SuperScript IV First-Strand Synthesis System (ThermoFisher Scientific). Quantitative real-time PCR analysis using the comparative Ct method was performed on the Applied Biosystem Vii 7 system (ThermoFisher Scientific) with the Powerup SYBR Master Mix (ThermoFisher Scientific) according to the manufacturer's instructions.
Chromatin immunoprecipitation
ChIP assay was performed according to Cold Spring Harbor protocol (54) . Briefly, cells were cross-linked for 
RNA-seq
ATDC5 stable cell lines (Kmt2d +/+ , Kmt2d DR5551/-, Kmt2d -/-) were seeded at 1× 10 5 cells/well in 6-well plates and allowed to adhere overnight in standard medium. The next day and every 2-3 days thereafter, medium was replaced with chondrogenic differentiation medium. Total RNA was isolated using TRIZOL reagent and RNA 
RNA-seq bioinformatics analysis
We first pseudoaligned the reads to a fasta file (Mus_musculus.GRCm38.cdna.all.fa.gz) obtained from Ensembl (http://uswest.ensembl.org/Mus_musculus/Info/Index, version 91, downloaded January 2018), which contained all mouse cDNA sequences, and then performed the quantification of transcript abundances using Salmon (55) .
Then, we utilized the tximport R package (56) in order to obtain normalized gene-level counts from the transcript abundances. To achieve this, we set the "countsFromAbundance" parameter equal to "lengthScaledTPM".
Subsequently, using the edgeR (57) and limma (58) R packages, we applied a log2 transformation to the genelevel counts and normalized each sample with the "voom" function in limma, using the effective library size (i.e.
the product of the library size and the normalization factors, calculated using the "calcNormFactors" function in edgeR). We then estimated the mean-variance relationship and computed weights for each observation. Since the differential expression analysis included technical replicates for each of three wild-type and two mutant clones, we fit a mixed linear model using the function "duplicateCorrelation" from the statmod R package (60), by blocking on the clone to account for the correlation among technical replicates. Finally, we performed the differential analysis with the limma R package with an FDR of 0.05 as the threshold for statistical significance.
Prior to performing the principal components analysis, we converted transcript abundances to gene-level counts using the tximport R package by setting the "countsFromAbundance" parameter to "no". Then, we first used the "vst" function from the DESeq2 R package (59) ; with the parameter "blind" set to "TRUE") in order to apply a variance stabilizing transformation to the obtained gene-level counts. Then, without standardizing the resulting expression matrix, we used the 1000 most variable genes to estimate the principal components.
Lentiviral transduction
Lenti-ORF particles, Shox2 (Myc-DDK-tagged) and Control (Myc-DDK-tagged) were purchased from Origene.
To transduce the ATDC5 cells, 1.2 × 10 5 cells/well were seeded in 6-well plates overnight and then transduced with the lentivirus at a multiplicity of infection (MOI) of 5 and with a final polybrene concentration of 8 ug/mL.
Statistics
One-sided unpaired student's t-test was used to calculate p values, unless otherwise noted; p < 0.05 indicated statistical significance.
Study approval
All experiments using laboratory mice were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Johns Hopkins Animal Care and Use Committee and performed in accordance with their guidelines.
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